PMN · XBRL financial data
ProMIS Neurosciences financial statements, every fiscal year
The same tables from 4 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (PMN's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|
| Research and development | 16,087 | 7,883 | 10,638 | 33,379 |
| General and administrative | 7,293 | 6,380 | 6,190 | 6,788 |
| Total operating expenses | 23,380 | 14,263 | 16,827 | 40,167 |
| Operating income (loss) | (23,380) | (14,263) | (16,827) | (40,167) |
| Interest expense | 282 | — | — | — |
| Other income (expense) | 116 | 385 | 626 | 443 |
| Income tax expense (benefit) | 0 | 0 | 0 | — |
| Net income (loss) | (18,062) | (13,212) | 2,779 | (39,719) |
| Earnings per share, basic‡ USD per share | (150,625.00) | (66,875.00) | 6,875.00 | (56,525.00) |
| Earnings per share, diluted‡ USD per share | (150,625.00) | (66,875.00) | 6,875.00 | (56,525.00) |
| Weighted average shares, basic‡ thousands of shares | 0 | 0 | 0 | 1 |
| Weighted average shares, diluted‡ thousands of shares | 0 | 0 | 0 | 1 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (November 2025); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-2500 stock split (November 2025); filings made before it reported them unadjusted.
- † Share count changed about 7x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (PMN's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|
| Cash and cash equivalents | 5,876 | 12,598 | 13,291 | 6,117 |
| Short-term investments | 31 | 32 | 33 | 34 |
| Prepaid and other current assets | 997 | 989 | 5,587 | 3,032 |
| Total current assets | 6,903 | 13,619 | 18,911 | 9,182 |
| Property and equipment, net | 0 | — | — | — |
| Total assets | 6,925 | 13,619 | 18,911 | 9,182 |
| Accounts payable | 2,975 | 7,843 | 1,737 | 2,543 |
| Accrued liabilities | 3,438 | 1,507 | 481 | 7,868 |
| Total current liabilities | 6,413 | 9,350 | 2,218 | 10,412 |
| Total liabilities | 8,272 | 9,866 | 2,423 | 10,441 |
| Accumulated deficit | (80,253) | (93,466) | (90,687) | (130,406) |
| Total stockholders' equity | (1,348) | 3,753 | 16,488 | (1,259) |
| Total liabilities and equity | 6,925 | 13,619 | 18,911 | 9,182 |
| Common shares outstanding (cover page)‡ thousands of shares | 0 | 0 | 1 | 4 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (November 2025); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-2500 stock split (November 2025); filings made before it reported them unadjusted.
- † Share count changed about 7x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (PMN's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|
| Net income (loss) | (18,062) | (13,212) | 2,779 | (39,719) |
| Stock-based compensation | 488 | 272 | 826 | 858 |
| Net cash from operating activities | (17,034) | (10,844) | (27,182) | (28,119) |
| Purchases of property and equipment | 2 | — | — | — |
| Net cash from investing activities | (2) | (1) | (1) | (1) |
| Proceeds from issuing common stock | 4,974 | — | 190 | 708 |
| Net cash from financing activities | 6,495 | 17,749 | 27,876 | 20,945 |
| Net change in cash | (11,068) | 6,722 | 693 | (7,175) |
- † Share count changed about 7x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| ProMIS Neurosciences | 53,429 | not reported | (10,385)* | 9.0M | 5.1 quarters | 10-QJun 30, 2026 |
| Cumberland Pharmaceuticals | 3,862 | 166 | 169* | 15.0M | — | 10-QJun 30, 2026 |
| Tempest Therapeutics | 779 | not reported | (2,779)* | 16.0M | 0.3 quarters | 10-QJun 30, 2026 |
| Provectus Biopharmaceuticals | 1,157 | not reported | (358)* | 420.3M | 3.2 quarters | 10-QJun 30, 2026 |
| Rockwell Medical | 10,519 | not reported | 2,080* | 4.0M | — | 10-QJun 30, 2026 |
| Champions Oncology | 4,358 | 15,232 | (492) | 13.9M | 8.0 quarters | 10-QJul 31, 2026 |
| OnKure Therapeutics | 166,502 | not reported | (10,354)* | 40.5M | 17.0 quarters | 10-QJun 30, 2026 |
| Yarrow Bioscience | 22,925 | 97 | (1,992)* | 2.7M | 11.5 quarters | 10-QJun 30, 2026 |
| Rein Therapeutics | 8,542 | 0 | (8,640)* | 86.3M | 4.7 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.